News & Updates

Show Multimedia Only

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

24 Jun 2024

Identifying hypersensitivity reactions to anticancer chemotherapy and monoclonal antibodies may help clinicians improve management of patients with oncological diseases, suggests a study.

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

24 Jun 2024

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

24 Jun 2024 by

Treatment with vonoprazan, a potassium competitive acid blocker (P-CAB), successfully starts and sustains the healing of Los Angeles (LA) grade C/D esophagitis as compared with proton pump inhibitor (PPI) and has moderate short- and long-term safety, according to a study. On the other hand, other P-CAB therapies need more evidence to prove their advantages.

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

24 Jun 2024

Drugs.com detects more drug–drug interactions in breast cancer patients

24 Jun 2024

A recent study has found more potential drug‒drug interactions in breast cancer patients receiving doxorubicin and cyclophosphamide regimen in the Drugs.com database than in the Lexicomp and Micromedex databases.

Drugs.com detects more drug–drug interactions in breast cancer patients

24 Jun 2024

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

24 Jun 2024

In the treatment of critically ill patients with sepsis, continuous infusion of β-lactam antibiotics does not appear to significantly reduce 90-day mortality compared with intermittent infusions, according to the results of an open-label BLING III trial.

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

24 Jun 2024

Densiron improves visual outcomes in eyes with primary RRD

23 Jun 2024 by

Densiron, a heavier-than-water endotamponade agent, may be used in the treatment of primary rhegmatogenous retinal detachment (RRD) in eyes with predominantly inferior retinal pathology and proliferative vitreoretinopathy (PVR) grade C, as shown by its higher anatomic success rates and improved visual outcomes relative to conventional light silicone oil (LSO), suggests a study.

Densiron improves visual outcomes in eyes with primary RRD

23 Jun 2024

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial

21 Jun 2024 by

The investigational dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor survodutide helps reduce the histological activity of metabolic dysfunction-associated steatohepatitis (MASH) as well as improve fibrosis, according to the phase II 1404-0043 trial.

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial

21 Jun 2024

Does paternal use of metformin up risk for congenital malformations?

21 Jun 2024

Use of metformin monotherapy by fathers during the sperm development period prior to conception does not appear to contribute to an increased risk of major congenital malformations (MCMs) in newborns, reveals a study.

Does paternal use of metformin up risk for congenital malformations?

21 Jun 2024

Original New Drug Application Approvals by US FDA (1-15 June 2024)

21 Jun 2024

New drug applications approved by US FDA as of 1-15 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 June 2024)

21 Jun 2024

Multidrug-resistant bacterial infections prevalent after liver transplant

20 Jun 2024

Patients who underwent liver transplantation (LT) are vulnerable to multidrug-resistant bacteria (MDRB) infections, which can significantly affect their prognosis, suggests a study. The most common pathogen is Enterococcus faecium.

Multidrug-resistant bacterial infections prevalent after liver transplant

20 Jun 2024

Obeticholic acid reduces progression to cirrhosis in patients with MASH-related fibrosis

20 Jun 2024 by

Treatment with obeticholic acid (OCA) improves clinical outcome in patients with precirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH), with a reduction in histological progression to cirrhosis seen in those receiving the 25-mg dose, as seen in the final results of the REGENERATE study.

Obeticholic acid reduces progression to cirrhosis in patients with MASH-related fibrosis

20 Jun 2024

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

Hypersensitivity reactions to chemo, monoclonal antibodies offer clues in cancer management

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

Vonoprazan trumps PPIs for treatment of grade C/D esophagitis

Drugs.com detects more drug–drug interactions in breast cancer patients

Drugs.com detects more drug–drug interactions in breast cancer patients

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

No clear mortality benefit with continuous vs intermittent antibiotics in sepsis treatment

Densiron improves visual outcomes in eyes with primary RRD

Densiron improves visual outcomes in eyes with primary RRD

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial

Survodutide treatment for MASH with fibrosis scores high in mid-stage trial

Does paternal use of metformin up risk for congenital malformations?

Does paternal use of metformin up risk for congenital malformations?

Original New Drug Application Approvals by US FDA (1-15 June 2024)

Original New Drug Application Approvals by US FDA (1-15 June 2024)

Multidrug-resistant bacterial infections prevalent after liver transplant

Multidrug-resistant bacterial infections prevalent after liver transplant

Obeticholic acid reduces progression to cirrhosis in patients with MASH-related fibrosis

Obeticholic acid reduces progression to cirrhosis in patients with MASH-related fibrosis